---
title: CRISPR-Based Therapy for Hereditary Angioedema
date: '2024-10-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39445704/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241025210305&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: NTLA-2002 administered in a single dose of 25 mg or 50
  mg reduced angioedema attacks and led to robust and sustained reduction in total
  plasma kallikrein levels in patients with hereditary angioedema. These results support
  continued investigation in a larger phase 3 trial. (Funded by Intellia Therapeutics;
  ClinicalTrials.gov number, NCT05120830; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema. These results support continued investigation in a larger phase 3 trial. (Funded by Intellia Therapeutics; ClinicalTrials.gov number, NCT05120830; EudraCT number, ...